Crystalline Forms of a Pharmaceutical Compound

    公开(公告)号:US20230391724A1

    公开(公告)日:2023-12-07

    申请号:US18029842

    申请日:2021-10-01

    申请人: Azafaros B.V.

    IPC分类号: C07D211/46

    CPC分类号: C07D211/46 C07B2200/13

    摘要: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.

    Crystalline Forms of a Pharmaceutical Compound

    公开(公告)号:US20240287001A9

    公开(公告)日:2024-08-29

    申请号:US18029842

    申请日:2021-10-01

    申请人: Azafaros B.V.

    IPC分类号: C07D211/46

    CPC分类号: C07D211/46 C07B2200/13

    摘要: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.

    Crystalline forms of a pharmaceutical compound

    公开(公告)号:US12116344B2

    公开(公告)日:2024-10-15

    申请号:US18029842

    申请日:2021-10-01

    申请人: Azafaros B.V.

    IPC分类号: C07D211/46

    CPC分类号: C07D211/46 C07B2200/13

    摘要: The present invention relates to a crystalline form of compound (I) and a method of making the crystalline form of compound (I). The invention also provides pharmaceutical compositions comprising the crystalline form of compound (I). Furthermore, the invention relates to methods of using this crystalline form of compound (I) as a medicament and in the treatment of a disease involving abnormal levels of glucosylceramide and/or higher levels of glycosphingolipids.